# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection ...
Cantor Fitzgerald analyst Ross Osborn reiterates Elutia (NASDAQ:ELUT) with a Overweight and maintains $10 price target.
Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and lowers the price target from $11 ...
Elutia (NASDAQ:ELUT) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.33) by 2...
Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today anno...
Lake Street analyst Frank Takkinen maintains Elutia (NASDAQ:ELUT) with a Buy and raises the price target from $5 to $10.
Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and raises the price target from $5 t...
Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and raises the price target from $5 t...